Conference abstractPublished 29 Aug 2018
Iron chelation as a potential therapy for the treatment of Parkinsons disease
Kings College London, UK
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Inappropriate accumulation of iron in the dopaminergic region of the brain has been associated with ParkinsonâÂ?Â?s disease. Deferiprone is a selective, orally active iron chelator which has been used in several clinical trials designed to monitor its efficiency in the treatment of ParkinsonâÂ?Â?s disease. An improvement of both motor and mental performance has been observed in several patients. During such treatment, a decrease in the iron content of substantia nigra was observed using MRI. Unfortunately, deferiprone is associated with agranulocytosis, which occurs in a small percentage of patients. This necessitates weekly recording of white cells counts, which would not be ideal in the treatment of ParkinsonâÂ?Â?s disease patients. Over the past eight years we have been developing deferiprone analogues which are orally active, cross the blood brain barrier and (to the best of our knowledge) lack the agranulocytosis side effect. The properties of this molecular class will be discussed at the conference.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalNeurological Disorders
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “R C Hider”
